Breaking News

Celularity, Inc., accelerates breakthrough placental find & healing platform

—New Biotechnology Company Accelerates a Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory Degenerative Diseases, and Functional Regeneration

—Contributions of Capital, More Than 200+ Issued and Pending Patents, Pre-Clinical and Clinical Assets and Commercial Products Obtained from Companies Including Celgene Corporation, Sorrento Therapeutics (Nasdaq: SRNE), United Therapeutics (Nasdaq: UTHR), and Human Longevity, Inc.

WARREN, N.J.–(Antara/BUSINESS WIRE)– Celularity, Inc., a newly shaped biotechnology company, currently announced a acceleration of dungeon and hankie regenerative therapies to residence unmet medical needs in cancer and ongoing and degenerative disease. Celularity finished their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.

Celularity has been combined by a contributions of endless egghead property, clinical-stage assets, simple and clinical research, and growth imagination including:

    * Several clinical-stage immuno-oncology and regenerative medicine resources and a tube of pre-clinical assets
    * Proprietary allogeneic (“readily accessible”) immunotherapy platform
    * 200+ released and tentative patents in dungeon therapy; strong IP for placental branch cells
    * Broad entirely tellurian antibody-CAR constructs
    * IND-ready corner CD38 immuno-oncology programs
    * Commercial-stage organic metamorphosis products Biovance® and Interfyl®* and tube assets
    * LifeBankUSA branch dungeon biorepository with dual decades handling expertise

Founded on a pioneering work of Robert Hariri, MD, PhD, in tellurian placenta-derived mobile therapeutics and biomaterials, Celularity’s ability to gain placental branch cells, operative intensity therapies, and muster intensity treatments, positions it to strap a intensity of a tellurian placenta and work along a whole value chain.

“Celularity was shaped as a new biotechnology indication designed to request a required imagination to strap a placenta find height opposite a operation of unmet medical needs,” pronounced Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. “With a support of a investors, we are convention proven regenerative medicine record and imagination with a idea of building transformative therapies for deadly and bullheaded diseases.” Dr. Hariri was formerly chairman, arch systematic officer and arch executive officer of Celgene Cellular Therapeutics and owner of Anthrogenesis Corporation, that Celgene acquired in 2002. Dr. Hariri is also a co-founder of Human Longevity, Inc.

The arrangement of Celularity leverages seminal work in a find of novel biologically active dungeon populations in a tellurian placenta with extended healing potential. Celularity will pull on these exclusive and scalable discoveries that get from a post-partum tellurian placenta – an reliable and renewable source of serviceable biomaterials. Celularity’s growth module is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a different race of informed-consent donors.

Andrew von Eschenbach, MD, among a first members of a Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of a National Cancer Institute said, “The pioneering work of Celularity owner Bob Hariri has unleashed a singular properties of placental subsequent branch cells that have renewed wish for formulating protected and effective therapies for a many severe degenerative diseases.” Dr. von Eschenbach combined “Celularity with a concentration on accelerating origination in regenerative medicine can turn a heading matter for dungeon therapy to residence many of a world’s unmet medical needs.”

*Interfyl is a purebred heading of Alliqua BioMedical, Inc.

Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, “We are really vehement to attend in a origination of Celularity together with Dr. Hariri and his systematic group as good as tellurian heading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The intensity for regenerative therapies in treating a far-reaching array of ongoing degenerative conditions is good known. We see critical synergies for a oncology margin and a intensity to raise a quarrel opposite virulent cancers. Celularity’s technologies, assets, and resources will assistance allege comparison Sorrento mobile therapy programs and potentially renovate autologous mobile therapies into affordable and permitted allogeneic dungeon therapies.”

About Celularity, Inc.

Celularity, headquartered in Warren, New Jersey, is a biotechnology association with proprietary, leading-edge record and Intellectual Property to strap a energy of a placenta. Their medicine item portfolio consists of some-more than 200 released or tentative patents as good as pre-clinical and clinical resources including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and blurb theatre biosourcing and organic metamorphosis businesses. For some-more information, greatfully revisit www.celularity.com. Follow Celularity on Social Media: @Celularity.

About United Therapeutics

United Therapeutics Corporation is a biotechnology association focused on a growth and commercialization of innovative products to residence a unmet medical needs of patients with ongoing and life-threatening conditions.

About Sorrento Therapeutics

Sorrento is an antibody-centric, clinical theatre biopharmaceutical association building new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento’s lead product possibilities embody immunotherapies focused on a diagnosis of both plain tumors and hematological malignancies, as good as late theatre pain products. For some-more information, greatfully revisit http://sorrentotherapeutics.com

About Human Longevity, Inc.

Human Longevity, Inc. (HLI) is a genomics-based, health comprehension association formulating a world’s largest and many extensive database of whole genome, phenotype and clinical data. HLI is building and requesting vast scale computing and appurtenance training to make novel discoveries to change health. In further to a HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes a HLI Health Nucleus, a genomic powered clinical investigate core that uses whole genome method analysis, modernized clinical imaging and innovative appurtenance learning, along with curated personal health information, to broach a many finish design of particular health. For some-more information, greatfully revisit http://www.humanlongevity.com or http://www.healthnucleus.com

View source chronicle on businesswire.com: http://www.businesswire.com/news/home/20170821005809/en/

Contacts

Media:
For Celularity
Olivia Goodman, 212-715-1597
olivia.goodman@finnpartners.com
or
Sorrento Therapeutics, Inc.
Alexis Nahama, DVM, 858-203-4120
anahama@sorrentotherapeutics.com

Source: Celularity, Inc.

Article source: http://www.antaranews.com/en/news/112346/celularity-inc-accelerates-breakthrough-placental-discovery--therapeutic-platform

Related posts

CRRC Group, e-Gle conclude partnership agreement to produce in-wheel motors for EVs

Times of News

Eid al-Fitr exodus must be smooth and safe: Transportation Minister

Times of News

India accused of indiscriminately shelling in Pakistan’s Kashmir

Times of News